Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan
European Journal of Dermatology · 2024
DOI: 10.1684/ejd.2024.4750 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Dermatology, 2024. Verfasst von Teppei Hagino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Niazi, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Severity of Illness Index. Die Arbeit wurde bisher 11-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Niazi, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Fujimoto Dermatology Clinic, Funabashi, Japan.
Zitieren
APA
Hagino, T., Onda, M., Saeki, H., Fujimoto, E., & Kanda, N. (2024). Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan. European Journal of Dermatology. https://doi.org/10.1684/ejd.2024.4750
Vancouver
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan. European Journal of Dermatology. 2024. doi:10.1684/ejd.2024.4750
BibTeX
@article{Hagino2024,
author = {Hagino, Teppei and Onda, Marina and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan},
journal = {European Journal of Dermatology},
year = {2024},
doi = {10.1684/ejd.2024.4750}
}
EUVIMED